Skip to main content
Clinical Trials/NCT06418932
NCT06418932
Recruiting
Not Applicable

Compression Therapy of the Lower Limbs in Patients With Decompensated Heart Failure and Predominant Systemic Tissue Congestion

Fundación para la Investigación del Hospital Clínico de Valencia8 sites in 1 country106 target enrollmentMay 27, 2024
ConditionsHeart Failure

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Failure
Sponsor
Fundación para la Investigación del Hospital Clínico de Valencia
Enrollment
106
Locations
8
Primary Endpoint
Natriuresis
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

Randomized 1:1 multicenter double-blind clinical investigation evaluating the efficacy and safety of compression therapy of the lower limbs plus parenteral administration of diuretics vs. administration of parenteral diuretics alone (standard treatment) in patients with decompensated HF and predominantly systemic tissue congestion and absence of intravascular systemic congestion.

Patients will be assigned to standard treatment (parenteral administration of furosemide) versus parenteral administration of furosemide plus lower limb compression therapy for up to 72 hours. The dose of furosemide in all participants will be based on the clinical judgment of the responsible healthcare professional.

Registry
clinicaltrials.gov
Start Date
May 27, 2024
End Date
July 1, 2026
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Fundación para la Investigación del Hospital Clínico de Valencia
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients aged 18 years or older.
  • Patient with clinical judgment of acute decompensated heart failure in the first 96 hours from the start of parenteral diuretic treatment.
  • Patient treated with furosemide at least 40 mg in the last 24 hours.
  • NT-proBNP levels\>1000 pg/ml at least 1 time since the onset of decompensation.
  • Presence of tibio-malleolar edema at least grade II/IV at the time of inclusion.
  • Inferior vena cava (IVC) diameter on ultrasonography ≤21 mm at the time of the "screening" visit.

Exclusion Criteria

  • Being admitted to the Intensive Care Unit.
  • Renal transplant, chronic renal failure stage 5 (eGFR \<15 ml/min/1.73m2) or being included in dialysis program (peritoneal/hemodialysis) or in need of ultrafiltration.
  • Absence of peripheral pulses.
  • Ankle brachial index (ABI) \<0.
  • History of severe peripheral artery disease.
  • Previous intolerance to compressive bandaging.
  • HF secondary to acute myocardial infarction.

Outcomes

Primary Outcomes

Natriuresis

Time Frame: 24 hours

Changes in natriuresis at 24 hours after randomization.

Weight

Time Frame: 24 hours

Changes in weight at 24 hours after randomization

Secondary Outcomes

  • Inferior vena cava diameter(72 hours)
  • CA125(15±3 days)
  • Doses of furosemide(72 hours)
  • Time to oral administration.(72 hours)
  • Diameter of the lower limbs(72 hours)
  • Congestion score(72 hours)
  • NT-proBNP(72 hours)

Study Sites (8)

Loading locations...

Similar Trials